Seroatlas · Human Serome Atlas

ACTBL2

Beta-actin-like protein 2

Also known as: ACTBL_HUMAN, DKFZp686D0972

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q562R1
Gene: ACTBL2
Ensembl: ENSG00000169067
Chromosome: 5
Canonical length: 376 aa
Protein class: Plasma proteins, Predicted intracellular proteins

OverviewNCBI Gene

Predicted to enable protein kinase binding activity. Predicted to be a structural constituent of postsynaptic actin cytoskeleton. Predicted to be involved in axonogenesis and cell motility. Located in extracellular exosome. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

376 residues, UniProt reviewed canonical sequence.

>Q562R1|ACTBL2
     1  MTDNELSALV VDNGSGMCKA GFGGDDAPRA VFPSMIGRPR HQGVMVGMGQ KDCYVGDEAQ
    61  SKRGVLTLKY PIEHGVVTNW DDMEKIWYHT FYNELRVAPD EHPILLTEAP LNPKINREKM
   121  TQIMFEAFNT PAMYVAIQAV LSLYASGRTT GIVMDSGDGV THIVPIYEGY ALPHAILRLD
   181  LAGRDLTDYL MKILTERGYN FTTTAEREIV RDVKEKLCYV ALDFEQEMVR AAASSSPERS
   241  YELPDGQVIT IGNERFRCPE AIFQPSFLGI ESSGIHETTF NSIMKCDVDI RKDLYANTVL
   301  SGGSTMYPGI ADRMQKEIIT LAPSTMKIKI IAPPERKYSV WIGGSILASL STFQQMWISK
   361  QEYDEAGPPI VHRKCF

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against ACTBL2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.24
Highest tissue expression: 0.6 nTPM

Expression across tissuesHPA

Tissue

skin: 0.6 nTPM
cervix: 0.2 nTPM
salivary gland: 0.1 nTPM
testis: 0.1 nTPM
adipose tissue: 0 nTPM
adrenal gland: 0 nTPM

Single-cell type

early spermatids: 4.3 nCPM
breast myoepithelial cells: 2.6 nCPM
adipocytes: 1.6 nCPM
endometrial secretory cells: 1.3 nCPM
late spermatids: 1.2 nCPM
conjunctival goblet cells: 1 nCPM

Immune cell

basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM
MAIT T-cell: 0 nTPM

Brain region

amygdala: 0 nTPM
basal ganglia: 0 nTPM
cerebellum: 0 nTPM
cerebral cortex: 0 nTPM
choroid plexus: 0 nTPM
hippocampal formation: 0 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about ACTBL2.

Disease | ImmuneIEDB

Conditions an epitope on ACTBL2 was assayed in.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.95
gnomAD pLI: 0
gnomAD missense Z: -0.36
DepMap mean gene effect: 0.07
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of ACTBL2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads ACTBL2 as an antibody target. Whether an autoantibody or antibody against ACTBL2 could matter depends on whether native ACTBL2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

ACTBL2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label ACTBL2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...